Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)
Latest Information Update: 23 Jul 2021
At a glance
- Drugs Baltaleucel-T (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms PREVALE
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 27 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2019 Planned End Date changed from 16 Feb 2022 to 16 Apr 2022.